VJHemOnc is committed to improving our service to you

ASH 2019 | Tangible benefit for FLT3-ITD R/R AML on quizartinib

VJHemOnc is committed to improving our service to you

Mark Levis

Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the characterization of response and transfusion independence in relapsed/refractory FLT3-ITD mutated acute myeloid leukemia (AML) patients treated with quizartinib or salvage chemotherapy on the QuANTUM-R trial (NCT02039726). This revealed a tangible benefit from quizartinib. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter